Sarepta Advances Huntington's Therapy into Human Trials
Event summary
- Sarepta Therapeutics submitted a Clinical Trial Application (CTA) for SRP-1005 (formerly ARO-HTT) to Medsafe in New Zealand.
- The INSIGHTT Phase 1 trial, expected to begin in Q2 2026, will enroll approximately 24 participants.
- SRP-1005 is an siRNA therapy designed to target and reduce the huntingtin protein, a key driver of Huntington’s Disease.
- Preclinical data suggest SRP-1005 can achieve significant protein knockdown in deep brain regions.
The big picture
Sarepta’s entry into the Huntington’s Disease therapeutic space represents a significant expansion of its pipeline beyond rare muscular dystrophies. Huntington’s Disease, affecting an estimated 40,000 people in the U.S. alone, presents a substantial unmet medical need and a potential multi-billion dollar market if Sarepta can demonstrate efficacy with SRP-1005. The company’s reliance on siRNA technology, while promising, also carries inherent risks related to delivery and potential off-target effects.
What we're watching
- Regulatory Approval
- The speed of Medsafe's approval will dictate the timeline for initiating the INSIGHTT trial and subsequent development milestones, potentially impacting investor sentiment.
- Clinical Efficacy
- Early data from the Phase 1 trial will be critical in assessing the therapeutic potential of SRP-1005, as Huntington's disease has historically seen limited treatment options.
- Delivery Efficiency
- The success of Sarepta’s TfR1 delivery approach in achieving consistent and robust blood-brain barrier penetration will be a key determinant of the therapy's overall effectiveness.
Related topics